XML 117 R53.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaborative and Other Relationships (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until GAZYVA First Non-CLL FDA Approval | 40.0 | %
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL. First GAZYVA Threshold Date means the earlier of (i) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $150.0 million or (ii) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $150.0 million. Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.
Pretax profit sharing formula | Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Years Ended December 31,
(In millions) | 2017 |  | 2016 |  | 2015
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ | 1,316.4 |  |  | $ | 1,249.5 |  |  | $ | 1,269.8 |
Other revenues from anti-CD20 therapeutic programs | 242.8 |  |  | 65.0 |  |  | 69.4 |
Total revenues from anti-CD20 therapeutic programs | $ | 1,559.2 |  |  | $ | 1,314.5 |  |  | $ | 1,339.2 |
Summary of activity related to collaboration with AbbVie Inc. | The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:
| For the Year Ended December 31,
(In millions) | 2017 |  | 2016
Product revenues, net | $ | 53.1 |  |  | $ | 6.1 |
Costs and expenses | 92.6 |  |  | 50.0 |
Co-promotion losses in the U.S. | $ | 39.5 |  |  | $ | 43.9 |
Biogen's share of co-promotion losses in the U.S. | $ | 16.9 |  |  | $ | 21.9 |
Summary of activity related to collaboration with Eisai | A summary of activity related to the Eisai Collaboration Agreement is as follows:
| For the Years Ended December 31,
(In millions) | 2017 |  | 2016 |  | 2015
Total development expense incurred by the collaboration in development of BAN2401 and E2609 | $ | 146.2 |  |  | $ | 95.1 |  |  | $ | 84.1 |
Biogen's share of BAN2401 and E2609 development expense reflected in our consolidated statements of income, excluding upfront and milestone payments | $ | 74.3 |  |  | $ | 50.5 |  |  | $ | 40.4 |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block] + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of activity related to collaboration with company seven. + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration